Biogen Signs a License Agreement with Innocare for Orelabrutinib to Treat Multiple Sclerosis

 Biogen Signs a License Agreement with Innocare for Orelabrutinib to Treat Multiple Sclerosis

Biogen Signs a License Agreement with Innocare for Orelabrutinib to Treat Multiple Sclerosis

Shots:

  • InnoCare to receive $125M as up front & is eligible to receive ~ $812.5M as development & commercial milestones, following the achievement of definite milestones along with royalties on sales of any product resulting from the collaboration
  • Biogen to get exclusive rights for orelabrutinib to treat MS globally & other autoimmune diseases outside of China while InnoCare will retain exclusive WW rights to the therapy in the field of oncology & other autoimmune diseases in China
  • Orelabrutinib is a covalent BTKi with high selectivity & has the potential to cross the BBB. Additionally, the therapy is currently being evaluated in a P-II trial for RRMS

Click here to read full press release/ article | Ref: Globe Newswire | Image: Innocare

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post